These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1755008)

  • 1. The nitric oxide donor SIN-1 is a potent inhibitor of plasminogen activator inhibitor release from stimulated platelets.
    Drummer C; Lüdke S; Spannagl M; Schramm W; Gerzer R
    Thromb Res; 1991 Sep; 63(5):553-6. PubMed ID: 1755008
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of nitric oxide donors on the release of plasminogen activator inhibitor (PAI) from rabbit platelets in vitro.
    Korbut R; Marcinkiewicz E; Cieślik K; Gryglewski RJ
    J Physiol Pharmacol; 1995 Mar; 46(1):37-44. PubMed ID: 7599336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
    Fisch A; Michael-Hepp J; Meyer J; Darius H
    Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between SIN-1 and prostacyclin in inhibiting platelet aggregation.
    Bult H; Fret HR; Herman AG
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S120-3. PubMed ID: 2484689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic phosphorylation of platelet rap1B by SIN-1 and iloprost.
    Grünberg B; Negrescu E; Siess W
    Eur J Pharmacol; 1995 Feb; 288(3):329-33. PubMed ID: 7539769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of platelet activating factor-induced platelet aggregation by molsidomine, SIN-1, and nitrates in vitro and ex vivo.
    Gerzer R; Drummer C; Karrenbrock B; Heim JM
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S115-9. PubMed ID: 2484688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiadhesive and antithrombotic effects of the nitric oxide donor SIN-1 are combined with a decreased vasoconstriction in a porcine model of balloon angioplasty.
    Provost P; Tremblay J; Merhi Y
    Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1806-12. PubMed ID: 9327781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo.
    Spiecker M; Darius H; Meyer J
    Thromb Res; 1993 Jun; 70(5):405-15. PubMed ID: 7690993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct inhibition of platelet function by organic nitrates via nitric oxide formation.
    Weber AA; Strobach H; Schrör K
    Eur J Pharmacol; 1993 Sep; 247(1):29-37. PubMed ID: 8258358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of molsidomine on fibrinolytic activity: a double-blind, randomized study].
    Darius H; Grodzinska L; Hafner G; Meyer J
    Z Kardiol; 1991; 80 Suppl 5():47-50. PubMed ID: 1776335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of SIN-1, a metabolite of molsidomine, on paf-acether-blood platelets interactions].
    Nunez D; Russo-Marie F; Benveniste J
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):215. PubMed ID: 3550639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro inhibition of human and rat platelets by NO donors, nitrosoglutathione, sodium nitroprusside and SIN-1, through activation of cGMP-independent pathways.
    Priora R; Margaritis A; Frosali S; Coppo L; Summa D; Di Giuseppe D; Aldinucci C; Pessina G; Di Stefano A; Di Simplicio P
    Pharmacol Res; 2011 Sep; 64(3):289-97. PubMed ID: 21539916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of coronary artery thrombosis by SIN-1, a donor of nitric oxide.
    Ovize M; de Lorgeril M; Cathignol D; Delaye J; Renaud S
    J Cardiovasc Pharmacol; 1990 Oct; 16(4):641-5. PubMed ID: 1706807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of molsidomine on ex vivo platelet aggregation and plasma guanosine 3':5'-cyclic monophosphate levels in healthy volunteers.
    Karrenbrock B; Heim JM; Gerzer R
    Klin Wochenschr; 1990 Feb; 68(4):213-7. PubMed ID: 2156106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molsidomine.
    Reden J
    Blood Vessels; 1990; 27(2-5):282-94. PubMed ID: 2242448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of SIN-1 on platelet Ca2+ handling in patients with suspected coronary artery disease: ex vivo and in vitro studies.
    Le Quan Sang KH; Le Feuvre C; Brunet A; Pham TD; Metzger JP; Vacheron A; Devynck MA
    Thromb Haemost; 2000 May; 83(5):752-8. PubMed ID: 10823274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term exposure of endothelial cells to molsidomine increases their antithrombogenicity by inducing the production of nitric oxide-related chemical substances.
    Berenger-Bahuet FP; Rolland PH
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S98-105. PubMed ID: 2484710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide stimulates the phosphorylation of rap1b in human platelets and acts synergistically with iloprost.
    Reep BR; Lapetina EG
    Biochem Biophys Res Commun; 1996 Feb; 219(1):1-5. PubMed ID: 8619788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of platelet arachidonic acid liberation by endothelium-derived relaxing factor (EDRF) as studied with sin-1, a nitric oxide generating drug. Evidence for calcium-dependent and calcium-independent mechanisms.
    Gassama-Diagne A; Simon MF; Chap H
    J Lipid Mediat; 1992 Feb; 5(1):61-75. PubMed ID: 1327266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.